1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6F6BFC14A1AB459CD65257D5D00368441
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/roles-resourcing-and-management-of-medical-science-liaisons
18
19
203.234.214.113
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services

Roles, Resourcing and Management of Medical Science Liaisons

ID: PSM-234


Features:

26 Info Graphics

29 Data Graphics

350+ Metrics

3 Narratives

16 Best Practices


Pages: 66


Published: 2014


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

Buy this research as part of a

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
As the medical science liaison (MSL) function continues to gain importance in building and strengthening KOL relationships, medical affairs leaders are continually re-assessing their MSL management practices to be successful in the competitive environment.

Best Practices, LLC undertook this research to examine the growing roles and responsibilities of Medical Science Liaisons within leading healthcare organizations. The study captures critical insights across MSL operational, performance, and management fronts which includes the headcount, span of control, deployment factors, volume and mode of thought leader interactions, and medical science liaison performance measurement.

Medical Affairs leaders can use this study as a benchmark for future strategic and resource planning and best-practice implementation for the medical science liaison function.


Industries Profiled:
Pharmaceutical; Biotech; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories; Consumer Products; Diagnostic; Chemical


Companies Profiled:
Abbott Labs; Jazz Pharmaceuticals; Kadmon Pharmaceuticals; Covidien; Medtronic; BARD; Sanofi; Gilead Sciences; Abbvie; Bayer Healthcare; Vertex Pharmaceuticals; Biogen Idec; Amgen; Astellas; AstraZeneca; Baxter Healthcare; Boehringer Ingelheim; Celgene; Cubist Pharmaceuticals; Eisai; Genentech; GlaxoSmithKline; Ipsen; Laboratories Esteve; Merz Pharma; Mitsubishi Tanabe Pharma America; Merck Sharp & Dohme; Novartis; Shire; Takeda; Teva (branded); ViroPharma Inc; ViiV Healthcare

Study Snapshot

Nineteen participants from 15 leading pharmaceutical, biotech, and medical device companies contributed benchmark survey data and qualitative insights to this research. This study also provides longitudinal data comparisons with a similar benchmark study conducted in 2011.

Sample Key Findings

Factors for Right-Sizing MSL Field Force Size & Distribution: MSLs are an expensive and limited resource; it is critical to right-size MSL headcount and field distribution to support education and therapy growth. Thought leader concentration and product lifecycle plan are the two most effective factors in determining the MSL field force size. Interestingly, while revenue potential seems to have shrunk in importance as a driver for MSL deployment, distribution of sales force as a factor has increased in importance. Other important factors reported by benchmark companies include ratio of MSLs to product/franchise revenue and corporate commitment to an over-arching franchise.


Table of Contents

Executive Summary pp. 3-8
Research Overview pp. 3-4

Participating Companies pp. 5

High-level Findings & Insights pp. 6-8

Universe of Learning pp. 9-12

Specialist Role and Service Scope pp. 13-20

KOL Relationship Management pp. 21-25

Resource Management: MSL Investment Levels pp. 26-35

Value Associated with MSL & Measuring Effectiveness pp. 36-47

Budget Allocated to MSL Teams pp. 48-53

Top Challenges pp. 54-58

Lessons Learned pp. 59-65

About Best Practices, LLC pp. 66


List of Charts & Exhibits

Professional background of research participants

  • Number of approved products supported through MSL teams of benchmark participants
  • Oversight responsibility for Medical Science Liaison function
  • Extent of MSL involvement in the product development process
  • MSL involvement in stages of clinical trails
  • Factors driving deployment of MSLs
  • Stakeholder needs that drive MSL alignment
  • Percentage of annual MSL interactions per thought leader type
  • Number of visits from Medical Science Liaisons to maintain / develop relationships with regional and national level thought leaders
  • Outsourcing of MSL function
  • Control span over MSLs
  • Factors determining the number of MSLs to deploy into field
  • Key factors for increasing count of MSLs
  • Key factors for decreasing count of MSLs
  • Value associated with MSL responsibilities
  • Effectiveness of quantitative and qualitative metrics in measuring the success of MSLs
  • Optimal re-allocation of time spent on MSL activities
  • Annual budget attributed for MSL function and the breakup of MSL budget
  • Funding source for MSL budget
  • Factors affecting annual MSL budget
  • Top MSL deployment challenges
  • Top challenges for MSLs
  • Important lessons to strengthen relationships and market position